» Articles » PMID: 32123207

Identification of Serum Biomarkers for Active Pulmonary Tuberculosis Using a Targeted Metabolomics Approach

Overview
Journal Sci Rep
Specialty Science
Date 2020 Mar 4
PMID 32123207
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Although tuberculosis (TB) is a severe health problem worldwide, the current diagnostic methods are far from optimal. Metabolomics is increasingly being used in the study of infectious diseases. We performed metabolome profiling to identify potential biomarkers in patients with active TB. Serum samples from 21 patients with active pulmonary TB, 20 subjects with latent TB infection (LTBI), and 28 healthy controls were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) followed by multivariate and univariate analyses. Metabolic profiles indicated higher serum levels of glutamate, sulfoxy methionine, and aspartate and lower serum levels of glutamine, methionine, and asparagine in active TB patients than in LTBI subjects or healthy controls. The ratios between metabolically related partners (glutamate/glutamine, sulfoxy methionine/methionine, and aspartate/asparagine) were also elevated in the active TB group. There was no significant difference in the serum concentration of these metabolites according to the disease extent or risk of relapse in active TB patients. Novel serum biomarkers such as glutamate, sulfoxy methionine, aspartate, glutamine, methionine, and asparagine are potentially useful for adjunctive, rapid, and noninvasive pulmonary TB diagnosis.

Citing Articles

Combined urine proteomics and metabolomics analysis for the diagnosis of pulmonary tuberculosis.

Yu J, Yuan J, Liu Z, Ye H, Lin M, Ma L Clin Proteomics. 2024; 21(1):66.

PMID: 39695396 PMC: 11657435. DOI: 10.1186/s12014-024-09514-4.


Alterations in purine and pyrimidine metabolism associated with latent tuberculosis infection: insights from gut microbiome and metabolomics analyses.

Yang B, Guo X, Shi C, Liu G, Qin X, Chen S mSystems. 2024; 9(11):e0081224.

PMID: 39436103 PMC: 11575419. DOI: 10.1128/msystems.00812-24.


Biomarkers in diagnosing and therapeutic monitoring of tuberculosis: a review.

Leo S, Narasimhan M, Rathinam S, Banerjee A Ann Med. 2024; 56(1):2386030.

PMID: 39097795 PMC: 11299445. DOI: 10.1080/07853890.2024.2386030.


Metabolomics for Clinical Biomarker Discovery and Therapeutic Target Identification.

Lin C, Tian Q, Guo S, Xie D, Cai Y, Wang Z Molecules. 2024; 29(10).

PMID: 38792060 PMC: 11124072. DOI: 10.3390/molecules29102198.


Exploring the Potential of Exosomes as Biomarkers in Tuberculosis and Other Diseases.

Arya R, Jit B, Kumar V, Kim J Int J Mol Sci. 2024; 25(5).

PMID: 38474139 PMC: 10931916. DOI: 10.3390/ijms25052885.


References
1.
Targowski T, Chelstowska S, Plusa T . IGRA as a predictive factor of silent pulmonary changes in individuals following exposure to tuberculosis. Lung. 2014; 192(6):869-74. PMC: 4237935. DOI: 10.1007/s00408-014-9637-y. View

2.
Isa F, Collins S, Lee M, Decome D, Dorvil N, Joseph P . Mass Spectrometric Identification of Urinary Biomarkers of Pulmonary Tuberculosis. EBioMedicine. 2018; 31:157-165. PMC: 6013777. DOI: 10.1016/j.ebiom.2018.04.014. View

3.
Dunn W, Bailey N, Johnson H . Measuring the metabolome: current analytical technologies. Analyst. 2005; 130(5):606-25. DOI: 10.1039/b418288j. View

4.
Gowda G, Raftery D . Biomarker Discovery and Translation in Metabolomics. Curr Metabolomics. 2016; 1(3):227-240. PMC: 4848463. DOI: 10.2174/2213235X113019990005. View

5.
Loots D . TB or not TB? Improving the understanding and diagnosis of tuberculosis through metabolomics. Biomark Med. 2016; 10(10):1025-1028. DOI: 10.2217/bmm-2016-0206. View